Page 4 - Repeatable Battery News Today

Patients with late-life schizophrenia (LLS) were associated with disturbances in the antioxidant system according to findings in BMC Psychiatry.

Acute supplementation with Nutrition 21’s inositol-stabilized arginine silicate ingredient may enhance cognitive function and memory in healthy aduts, says a new study.

A combination of omega-3 fatty acids, lutein, meso-zeaxanthin, and zeaxanthin, and vitamin E may improve working memory in cognitively healthy older adults, says a new study from Ireland.

Acute supplementation with Nutrition 21’s inositol-stabilized arginine silicate ingredient may enhance cognitive function and memory in healthy aduts, says a new study.

A combination of omega-3 fatty acids, lutein, meso-zeaxanthin, and zeaxanthin, and vitamin E may improve working memory in cognitively healthy older adults, says a new study from Ireland.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Patients with sickle cell disease showed impairments in some cognitive domains compared with healthy control individuals, according to a new study.

Aging-US published "Facility-based and home-based multidomain interventions including cognitive training, exercise, diet, vascular risk management, and motivation for older adults: a randomized controlled feasibility trial" which reported that in an outcome assessor-blinded, randomized controlled trial, participants without dementia and with one or more modifiable dementia risk factors, aged 60-79 years, were randomly assigned to the facility-based MI, the home-based MI, or the control...

16 Dec 2020 BACE inhibitors succeeded in stemming the tide of Aβ production in the brain, but the drugs also slightly dulled cognition and shrank the brain, bringing the trials to a screeching halt. Rather than washing their hands of a failure and moving on, researchers continue to dig through the trial data to find out exactly what happened, and perhaps even to chart a way forward for the drugs. Three recent studies—all led by Michael Egan at Merck—add new insight. Verubecestat triggered ...